Statins and Hip Fracture Prevention - A Population Based Cohort Study in Women

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Helin Salmivaara, Arja ^a,b   Korhonen, Maarit J ^a   Lehenkari, Petri ^c   Junnila, Seppo Y T ^d   Neuvonen, Pertti J ^e   Ruokoniemi, Päivi ^a,e,f   Huupponen, Risto ^a,f  

^a UNIVERSITY OF TURKU   (Finland)

^b HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d Salo Health Care Centre   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; FINLAND; FOLLOW UP; HAZARD RATIO; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INCIDENCE; LONG TERM CARE; LOW ENERGY HIP FRACTURE; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POPULATION RESEARCH; PREDICTIVE VALIDITY; PROPENSITY SCORE; RISK ASSESSMENT; WOMEN'S HEALTH;

AGED; ANTIHYPERTENSIVE AGENTS; BONE AND BONES; BONE DENSITY; COHORT STUDIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HIP FRACTURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; PATIENT COMPLIANCE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS;

EID: 84868130690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048095     Document Type: Article

References (44)

1. Mundy G, Garrett R, Harris S, Chan J, Chen D, et al. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949.
2. Horiuchi N, Maeda T, (2006) Statins and bone metabolism. Oral Dis 12: 85-101.
3. Fukui T, Ii M, Shoji T, Matsumoto T, Mifune Y, et al. (2012) Therapeutic effect of local administration of low dose simvastatin-conjugated gelatin hydrogel for fracture healing. J Bone Miner Res 27: 1118-31.
4. Hatzigeorgiou C, Jackson JL, (2005) Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16: 990-998.
5. Yue J, Zhang X, Dong B, Yang M, (2010) Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause 17: 1071-1079.
6. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY, (2007) Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40: 1581-1587.
7. Baim S, Leslie WD, (2012) Assessment of fracture risk. Curr Osteoporos Rep 10: 28-41.
8. Kijowski R, Tuite M, Kruger D, Munoz Del Rio A, Kleerekoper M, et al. (2012) Evaluation of trabecular micro-architecture in non-osteoporotic post-menopausal women with and without fracture. J Bone Miner Res 27: 1494-500.
9. Toh S, Hernandez-Diaz S, (2007) Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 16: 627-640.
10. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622.
11. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, et al. (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357: 509-512.
12. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, et al. (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355: 2185-2188.
13. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC, (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162: 537-540.
14. Bakhireva LN, Shainline MR, Carter S, Robinson S, Beaton SJ, et al. (2010) Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women. Pharmacotherapy 30: 879-887.
15. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, et al. (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164: 146-152.
16. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, et al. (2009) Statin adherence and risk of accidents: a cautionary tale. Circulation 119: 2051-2057.
17. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, et al. (2010) The Nordic Countries as a Cohort for Pharmacoepidemiological Research. Basic Clin Pharmacol Toxicol 106: 86-94.
18. WHO. About the ATC/DDD system. http://www.whocc.no/atcddd/. Accessed 4 Apr, 2008, 2008.
19. Sund R, Nurmi-Luthje I, Luthje P, Tanninen S, Narinen A, et al. (2007) Comparing properties of audit data and routinely collected register data in case of performance assessment of hip fracture treatment in Finland. Methods Inf Med 46: 558-566.
20. Leslie SR, Gwadry-Sridhar F, Thiebaud P, Patel BV, (2008) Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharmaceutical programming 1: 13-19.
21. Patrick AR, Schneeweiss S, Brookhart MA, Glynn RJ, Rothman KJ, et al. (2011) The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf 20: 551-559.
22. Sund R, (2007) Utilization of routinely collected administrative data in monitoring the incidence of aging dependent hip fracture. Epidemiol Perspect Innov 4: 2.
23. Rejnmark L, Vestergaard P, Mosekilde L, (2006) Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif Tissue Int 79: 27-36.
24. Han SL, Wan SL, (2012) Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract 66: 199-209.
25. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, et al. (2003) Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33: 805-811.
26. Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, et al. (2010) Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Regul Pept 162: 99-108.
27. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, et al. (2004) Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92: 458-471.
28. Monjo M, Rubert M, Ellingsen JE, Lyngstadaas SP, (2010) Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells. Cell Physiol Biochem 26: 647-656.
29. Ho ML, Chen YH, Liao HJ, Chen CH, Hung SH, et al. (2009) Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 39: 296-303.
30. Li X, Song QS, Wang JY, Leng HJ, Chen ZQ, et al. (2011) Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ERalpha expression and uterine wet weight in ovariectomized rats. J Bone Miner Metab 29: 396-403.
31. Rosen CJ, (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353: 595-603.
32. Virtanen JK, Mozaffarian D, Willett WC, Feskanich D Dietary intake of polyunsaturated fatty acids and risk of hip fracture in men and women. Osteoporos Int DOI: 10.1007/s00198-012-1903-3. [Epub ahead of print].
33. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, et al. (1992) Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 75: 45-51.
34. Cummings SR, Black D, (1995) Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 98: 24S-28S.
35. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P, (1996) Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 93: 1372-1379.
36. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, et al. (2007) Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166: 348-354.
37. National Agency for Medicines and Social Insurance Institution (1997) Finnish Statistics on Medicines 1996. Helsinki.
38. National Agency for Medicines and Social Insurance Institution (2007) Finnish Statistics on Medicines 2006. Helsinki.
39. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, et al. (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int DOI: 10.1007/s00198-012-1964-3. [Epub ahead of print].
40. Wells G, Cranney A, Peterson J, Boucher M, Shea B, et al. (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev: CD004523.
41. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, et al. (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev: CD001155.
42. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, et al. (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev: CD003376.
43. Ringe JD, Doherty JG, (2010) Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 30: 863-869.
44. Barrat AL, Wyer PC, Gyatt G, Simpson JM, (2005) NNT for studies with long-term follow-up. CMAJ 172: 613-615.